Have a look at the last investor update announcement. It states we should get a update of the phase 1 trial in Sept.
No adverse events reported from that trial so far, so hopefully CHM have got the CarT vs solid tumor problem solved.
Massive value right there if they can transfer that tech to other solid tumors, which is what they are investigating.
Ann: Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial, page-23
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |